AWAKN™ Life Sciences capitalises on evidence based Psychedelic Assisted Psychotherapy solutions to heal the mental state of the UK.
Awakn's focus is ensuring optimal patient safety, while delivering efficacy through transformative patient care, in conjunction with scientifically validating long-term mental health.
On-demand research and clinical trials – study design, enrollment, execution – for the medicalisation of psychedelic assisted therapy. Advancing mental health through pre-clinical, Phase I-III, regulatory submissions and IP creation.
A revolutionary shift in the treatment approach for mental health disorders, under the leadership of psychiatric specialist, researcher, author and clinic founder, Dr. Ben Sessa.
Scalable clinical training & knowledge management platform for Psychiatrists and Psychologists to understand the protocols and power of psychedelics as an aide to therapy. Includes modules for: live group events; training simulators and online video learning.
AWAKN Life Sciences Inc., is a patient first focused psychedelic business that is focused on the UK and is led by two stars in the space. They are currently doing an early round with a pre-money value of just over $4mm. Unlike most companies in the space, AWAKN expects to be generating revenue very quickly.
AWAKN has partnered with Dr. Ben Sessa, as it’s Chief Medical Officer, to open the first psychedelic assisted psychotherapy clinic in the UK. The UK is one of the largest markets in the world with an annual mental health costs of 90 BN, with 17% of the population being affected by mental health issues.
David Nutt is a leading Neuroscientist and drug policy reform advocate. Formerly the Chief Drug Advisor to the UK government. He is currently the Edmond J. Safra Professor of Neuropsychopharmacology and director of the unit in the Division of Brain Sciences at Imperial College London. He has published over 400 original research papers, 8 government reports on Drugs and 28 books. He is currently the President of the European Brain Council and Founding Chair of DrugScience , formerly the Independent Scientific Committee on Drugs (ISCD).